Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton

Contributed by: Business Wire

Logo

Tags

Professional Services

Health

Neurology

Finance

Pharmaceutical

Biotechnology

Ponvory Acquisition

More Like This

JOURNAVX bottle and tablet (Photo: Business Wire)

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

PR Newswire associated0

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

PR Newswire associated0

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®

PR Newswire associated0

Azurity Pharmaceuticals Completes Acquisition of Covis Pharma